Toxicological assessment of orally delivered nanoparticulate insulin

References

• Akbarzadeh A, Noruzian D, Jamshidi S, Farhangi A, Mehrabi MR, Lame Rad B., Mofidian M, Allahverdi A. Treatment of streptozotocin induced diabetes in male rats by immunoisolated transplantation of islet cells. Ind J Clin Biochem 2007; 22: 71–76
   PubMedGoogle Scholar
• Al-Achi A, Greenwood R. A brief report on some physiological parameters of streptozotocin-diabetic rat. Drug Dev Ind Pharm 2001; 27: 465–468
   PubMed Web of Science ®Google Scholar
• Barbas J. Nefropatia diabética. Diabetologia Clínica, R Duarte. Lidel-Edições Técnicas, Lda, Lisboa 1997; 255–269
   Google Scholar
• Cancercare (2007) 2007. TorontoCanada: Cancer Care Ontario; June 5; Available from the website: http://www.cancercare.on.ca/pdfdrugs/STREPTOZ.pdf.
   Google Scholar
• CaparrozAssef SM, Grespan R, Batista RCF, BersaniAmado FA, Baroni S, Dantas JA, Cuman RKN, Bersani-Amado CA. Toxicity studies of Cordia salicifolia extract. Acta Sci Health Sci 2005; 27: 4141–4144
   Google Scholar
• Cui F, Zhang L, Zheng J, Kawashima Y. A study of insulin-chitosan complex nanoparticles used for oral administration. J Drug Del Sci Tech 2004; 14: 435–439
   Web of Science ®Google Scholar
• Damgé C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin. Drug Deliv 2008; 5: 45–68
   Web of Science ®Google Scholar
• Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Rel 2007; 117: 163–170
   PubMed Web of Science ®Google Scholar
• Damgé C, Michel C, Aprahamian M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 1988; 37: 246–251
   PubMed Web of Science ®Google Scholar
• Delie F, Blanco-Príeto MJ. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 2005; 10: 65–80
   PubMed Web of Science ®Google Scholar
• des Rieux A, Fievez V, Garinot M, Schneider Y-J, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Rel 2006; 116: 1–27
   PubMed Web of Science ®Google Scholar
• Duarte R. Insulina. Diabetologia Clínica, R Duarte. Lidel-Edições Técnicas, Lda, Lisboa 1997; 139–151
   Google Scholar
• Duarte R, Zeller PV, Lisboa PE. Alterações oculares na Diabetes. Diabetologia Clínica, R Duarte. Lidel-Edições Técnicas, Lda, Lisboa 1997; 242–254
   Google Scholar
• Fazzari P, Penachioni J, Gianola S, Rossi F, Eickholt BJ, Maina F, Alexopoulou L, Sottile A, Comoglio PM, Flavell RA, et al. Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis. BMC Dev Biol 2007; 7: 55
   PubMed Web of Science ®Google Scholar
• FDA (2007) 2007. Guidance for Industry, Q3C-Tables and List. FDA. July 5; Available from the website: http://www.fda.gov/ohrms/dockets/98fr/01b-0431-gdl0001.doc.
   Google Scholar
• Fernandez-Urrusuno R, Fatal E, Porquet D, Feger J, Couvreur P. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol Appl Pharmacol 1995; 130: 272–279
   PubMed Web of Science ®Google Scholar
• Florence AT. Nanoparticle uptake by the oral route: Fulfilling its potential?. Drug Discovery Today: Technologies 2005; 2: 75–81
   PubMedGoogle Scholar
• Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate. J Control Rel 1995; 36: 39–46
   Web of Science ®Google Scholar
• Gabbay K. Hyperglycemia, polyol metabolism, and complication of diabetes mellitus. Ann Rev Med 1975; 26: 521–536
   PubMed Web of Science ®Google Scholar
• Gaspar R. Regulatory issues surrounding nanomedicines: Setting the scene for the next generation of nanopharmaceuticals. Future Nanomed 2007; 2: 143–147
   PubMed Web of Science ®Google Scholar
• Hamet P, Sugimoto H, Umeda F, Franks DJ. Platelets and vascular smooth muscle: abnormalities of phosphodiesterase, aggregation, and cell growth in experimental and human diabetes. Metabolism 1983; 32: 124–130
   PubMed Web of Science ®Google Scholar
• Healthbanks (2007) 2007. Blood urea nitrogen. Healthbanks. July 5; Available from the website: http://www.healthbanks.com/PatientPortal/Public/LinkPublic.do?ArticleID=HW5aa36271.
   Google Scholar
• Inal S, Yilmaz N, Nisbet C, Guvenc T, Samsun T. Biochemical and histopathological findings of N-butyl-2-cyanoacrylate in oral surgery: An experimental study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod :e 2006; 102: 14–17
   PubMed Web of Science ®Google Scholar
• Jacobson-Kram D, McGovern T. Toxicological overview of impurities in pharmaceutical products. Adv Drug Del Rev 2007; 59: 38–42
   PubMed Web of Science ®Google Scholar
• Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake?. Eur J Pharm Biopharm 2000; 50: 147–160
   PubMed Web of Science ®Google Scholar
• Kabanov AV. Polymer genomics: An insight into pharmacology and toxicology of nanomedicines. Adv Drug Del Rev Supplementary Non-Thematic Collection 2006; 58: 1597–1621
   PubMed Web of Science ®Google Scholar
• Karakilcik AZ, Hayat A, Aydilek N, Zerin M, Cay M. Effects of vitamin C on liver enzymes and biochemical parameters in rats anesthetized with halothane. Gen Physiol Biophys 2005; 24: 47–55
   PubMed Web of Science ®Google Scholar
• Kim JS, Yoon T-J, Yu KN, Kim BG, Park SJ, Kim HW, Lee KH, Park SB, Lee J-K, Cho MH. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci 2006; 89: 338–347
   PubMed Web of Science ®Google Scholar
• Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev 1991; 7: 71–86
   Web of Science ®Google Scholar
• Kume E, Aruga C, Ishizuka Y, Takahashi K, Miwa S, Itoh M, Fujimura H, Toriumi W, Kitamura K, Doi K. Gene expression profiling in streptozotocin treated mouse liver using DNA microarray. Exp Toxicol Pathol 2005; 56: 235–244
   PubMedGoogle Scholar
• Lerco MM, Spadella CT, Machado JLM, Schellini SA, Pavodini CR. Caracterização de um modelo experimental de Diabetes Mellitus, induzido pela aloxana em ratos. Estudo clínico e laboratorial. Acta Cirúrg. Bras 2003; 18: 136–142
   Google Scholar
• Lopes HJJ. (2007) 2007. Enzimas no laboratório clínico. Aplicações diagnósticas. July 2; Available from the website: www.goldanalisa.com.br/publicacoes/Enzimas_no_Laboratorio_Clinico.pdf,
   Google Scholar
• Ma Z, Lim TM, Lim L-Y. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int J Pharm 2005; 293: 271–280
   PubMed Web of Science ®Google Scholar
• Martin FJ, Miguez JM, Aldegunde M, Atienza G. Platelet serotonin transport is altered in streptozotocin-induced diabetic rats. Life Sci 1995; 56: 1807–1815
   PubMed Web of Science ®Google Scholar
• medicina.fm.usp.br (2007) 2007. São Paulo, Brasil; Faculdade de Medicina da Universidade de São Paulo; June 18; Available from the website: http://medicina.fm.usp.br/endoresidentes/roteiro/diabetes_mellitus_roteiro.pdf,
   Google Scholar
• Morinelli TA, Tempel GE, Jaffa AA, Silva RH, Naka M, Folger W, Halushka PV. Thromboxane A2/prostaglandin H2 receptors in streptozotocin-induced diabetes: Effects of insulin therapy in the rat. Prostaglandins 1993; 45: 427–438
   PubMed Web of Science ®Google Scholar
• Nanopharmaceuticals 2007. NanoPharmaceuticals.org; Available from the website: http://www.nanopharmaceuticals.org/Polymeric_nanoparticles.html.
   Google Scholar
• Oppenheim RC, Stewart NF, Gordon L, Patel HM. Production and evaluation of orally administered insulin nanoparticles. Drug Dev Ind Pharm 1982; 8: 531–546
   Web of Science ®Google Scholar
• Pan Y, Li Y, Zhao H, Zheng J, Xu H, Wei G, Hao J, Cui F. Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002; 249: 139–147
   PubMed Web of Science ®Google Scholar
• Priya CAYB, Anitha K, Mohan EM, Pillai KS, Murthy PB, Nadu T. Toxicity of fluoride to diabetic rats. Fluoride 1997; 30: 51–58
   Web of Science ®Google Scholar
• Quintana XG, Rodríguez MN, Sabo AG. Las plaquetas en la diabetes mellitus. Rev Cub Hematol Inmunol Hemoter 2001; 17: 19–24
   Google Scholar
• Reis C (2008) , Veiga F, Ribeiro A, Neufeld R, Damgé C. 2008. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J Pharm Sci [ ePub March 27, ] DOI: 10.1002/jps.21363.
   Google Scholar
• Reis CP, Neufeld RJ, Ribeiro, Antonio J, Veiga F. 2006a. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed: Nanotechnol, Biol Med 2:8–21.
   Google Scholar
• Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomed: Nanotechnol. Biol Med 2006b; 2: 53–65
   Google Scholar
• Reis CP, Ribeiro AJ, Houng S, Veiga F, Neufeld RJ. Nanoparticulate delivery system for insulin: Design, characterization and in vitro/in vivo bioactivity. Eur J Pharm Sci 2007; 30: 392–397
   PubMed Web of Science ®Google Scholar
• Reis CP, Ribeiro AJ, Neufeld RJ, Veiga F. Alginate microparticles as novel carrier for oral insulin delivery. Biotechnol Bioeng 2006c; 96: 977–989
   Web of Science ®Google Scholar
• Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm 2006; 325: 147–154
   PubMed Web of Science ®Google Scholar
• Sayim F, Yavasoglu NUK, Uyanikgil Y, Aktug H, Yavasoglu A, Turgut M. Neurotoxic effects of cypermethrin in Wistar rats: A haematological, biochemical and histophathologic study. J Health Sci 2005; 51: 300–307
   Google Scholar
• Tschöpe D, Schwippert B, Schettler B, Kiesel U, Rothe H, Roesen P, Gries FA. Increased GPIIB/IIIA expression and altered DNA-ploidy pattern in megakaryocytes of diabetic BB-rats. Eur J Clin Invest 1992; 22: 591–598
   PubMed Web of Science ®Google Scholar
• Umeda F, Adnot S, Franks DJ, Hamet P. Cyclic nucleotide phosphodiesterase and aggregation in platelets from diabetic rats. Metabolism 1982; 31: 704–709
   PubMed Web of Science ®Google Scholar
• Valentovic MA, Lubawy WC. Impact of insulin or tolbutamide treatment on 14C-arachidonic acid conversion to prostacyclin and/or thromboxane in lungs, aortas, and platelets of streptozotocin-induced diabetic rats. Diabetes 1983; 32: 846–851
   PubMed Web of Science ®Google Scholar
• Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 2003; 55: 519–548
   PubMed Web of Science ®Google Scholar
• Vega-Villa KR, Takemoto JK, Yáñez JA, Remsberg CM, Forrest ML, Davies NM. Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev 2008; 60: 929–938
   PubMed Web of Science ®Google Scholar
• Wijkstrom M, Kirchhof N, Graham M, Ingulli E, Colvin RB, Christians U, Hering BJ, Schuurman H-J. Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates. Toxicology 2005; 207: 117–127
   PubMed Web of Science ®Google Scholar
• Yngen M, Li N, Hjemdahl P, Wallen NH. Insulin enhances platelet activation in vitro. Thromb Res 2001; 104: 85–91
   PubMed Web of Science ®Google Scholar